Results 71 to 80 of about 45,703 (244)

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Advanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu, Ling Peng, Lu Lu, Huiyi Feng, Yan Zhong, Guisen Tan, Zhicheng Zhang, Liqin Huang, Chao Su, Ying Xue, Shuo Song, Wenxia Fan, Wei Wang, Fan Zou   +24 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Memory NK cell features exploitable in anticancer immunotherapy [PDF]

, 2019
Besides their innate ability to rapidly produce effector cytokines and kill virus-infected or transformed cells, natural killer (NK) cells display a strong capability to adapt to environmental modifications and to differentiate into long-lived ...
Battella, Simone, Capuano, Cristina, Galandrini, Ricciarda, Palmieri, Gabriella, Pighi, Chiara, Santoni, Angela   +5 more
core   +2 more sources

Antibody‐Empowered Nanomedicine for Precise Biomedical Applications

Advanced Science, EarlyView.
This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen, Xinglin Chen, Zhenhao Gao, Meng Sun, Yaozong Yu, Fang Lv, Qiujun Wang, Jinfeng Zhang   +7 more
wiley   +1 more source

Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity

Advanced Science, EarlyView.
The inhibitory immune checkpoints HLA‐G and CD47 are expressed on certain tumor types and inhibit immune cells in the tumor microenvironment. DSP216 binds specifically to cancer cells expressing both HLA‐G and CD47, and blocks their inhibitory signaling.
Lisa J. Jacob, Liat Tamir, Mufeed Abdeen, Ami Tamir, Alexandra Aronin, Itai Bloch, Roy Kahn, Iris Pecker, Mark Tykocinski, Gerwin Huls, Yaron Pereg, Ayelet Chajut, Edwin Bremer   +12 more
wiley   +1 more source

Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects

mBio, 2019
Measuring Envelope (Env)-specific antibody (Ab)-dependent cellular cytotoxicity (ADCC)-competent Abs in HIV+ plasma is challenging because Env displays distinctive epitopes when present in a native closed trimeric conformation on infected cells or in a ...
Franck P. Dupuy, Sanket Kant, Alexandre Barbé, Jean-Pierre Routy, Julie Bruneau, Bertrand Lebouché, Cécile Tremblay, Marzena Pazgier, Andrés Finzi, Nicole F. Bernard   +9 more
doaj   +1 more source

Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women [PDF]

, 2014
Recent studies suggest that HIV-specific antibody-dependent cell-mediated cytotoxicity (ADCC) antibodies contribute to protective immunity against HIV.
Baum LL, Beth D. Jamieson, de Souza M, Gao F, HIV-1 subtypes, John Phair, Joyce R. Iwema, Kathryn Anastos, Leslie Neems, Linda L. Baum, Mardge H. Cohen, Mariana M. Mata, Shanna Dell   +12 more
core   +2 more sources

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Machine Learning‐Enhanced Random Matrix Theory Design for Human Immunodeficiency Virus Vaccine Development

Advanced Intelligent Discovery, EarlyView.
This study integrates random matrix theory (RMT) and principal component analysis (PCA) to improve the identification of correlated regions in HIV protein sequences for vaccine design. PCA validation enhances the reliability of RMT‐derived correlations, particularly in small‐sample, high‐dimensional datasets, enabling more accurate detection of ...
Mariyam Siddiqah, Muhammad Zulqarnain Zeb, Muhammad Husnain Zeb, Babar Shabbir   +3 more
wiley   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source